Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Ceri Bygrave, William Wilson, Rakesh Popat, Marquita Camilleri, Karthik Ramasamy, Matthew Streetly, Michael A. Chapman, Ruth M de Tute, Selina J Chavda, Elizabeth H. Phillips, Maria del Mar Cuadrado, Fuad Fananapazir, Charlotte Tyson, Sumaiya Kamora, James D. Cavenagh, Roger G Owen, Kwee Yong

Blood (2024) 144 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2024-199514

Published: 2024

Journal Articles

Safety and Efficacy of Dara-VTD Induction and Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients Presenting with Renal Failure - a Tertiary Centre UK Experience on Behalf of the UK-MRA

Adrian Maraj, Katharine Bailey, Asma Batool, Reuben Benjamin, Stella Bowcock, Kate Bramham, Madson Correia de Farias, Maria Cuadrado, Paul Donohoe, Arief Gunawan, John Jones, Majid Kazmi, Neeraj Kohli, Piers Patten, Victoria Potter, Sajitha Sachchithanantham, Matthew Streetly, Kirsty Cuthill

Blood (2024) 144 (Supplement 1): 7076.

https://doi.org/10.1182/blood-2024-211648

Published: 2024

Journal Articles

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Blood (2023) 142 (Supplement 1): 4971.

https://doi.org/10.1182/blood-2023-177624

Published: 2023

Journal Articles

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2023-186318

Published: 2023

Journal Articles

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Blood (2022) 140 (Supplement 1): 10191–10192.

https://doi.org/10.1182/blood-2022-166344

Published: 2022

Journal Articles

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Blood (2022) 140 (Supplement 1): 10106–10107.

https://doi.org/10.1182/blood-2022-169882

Published: 2022

Journal Articles

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Blood (2021) 138 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2021-150177

Published: 2021

Journal Articles

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Blood (2021) 138 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2021-147771

Published: 2021

Journal Articles

Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups

Ana M Metelo, PhD, Ieuan Walker, BSc, MSc, MBBS, Agnieszka Jozwik, PhD, Charlotte Graham, MRCP, BSc, MBBS, Charlotte Attwood, BMedSci, MBBS, MRCP, FRCPath, Katy Sanchez, BSc, MSc, Alan Dunlop, BSc, MSc, Kirsty Cuthill, FRCPath,MBBS,MRCP,PhD, Carmel Rice, FRACP, FRCPA, MBBS, Matthew Streetly, MD, Trevor Bentley, BSc, Bijan Boldajipour, PhD, Cesar Sommer, PhD, Barbra Sasu, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 1834.

https://doi.org/10.1182/blood-2019-124312

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Karthik Ramasamy, MD PhD, Spyros Kolovos, PhD, Guido Nador, MD, Rosemarie Finley, Matthew Streetly, MD, Bhuvan Kishore, Neil K Rabin, MD, Andrew D Chantry, PhD MD, Kwee Yong, MD PhD, John Ashcroft, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Mark T Drayson, Daniel Prieto-Alhambra, PhD MD, Cyrus Cooper, OBE, DL, FMedSci, Muhammad Kassim Javaid, MD PhD, Rafael Pinedo-Villanueva, PhD

Blood (2018) 132 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2018-99-114736

Published: 2018

Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Blood (2018) 132 (20): 2115–2124.

https://doi.org/10.1182/blood-2018-07-862334

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

Timothy Brighton, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, David Ghez, Brendan M. Weiss, MD, Andreas Kirsch, Hila Magen, MD, Mercedes Gironella, Dra., Albert Oriol, MD, Matthew Streetly, BMBS, MRCP, MRCPath, Xiang Qin, Rajesh Bandekar, Peter Hu, Ming Qi, MD PhD, Sepideh Nemat, MD PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3155.

https://doi.org/10.1182/blood.V130.Suppl_1.3155.3155

Published: 2017

Journal Articles

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Blood (2016) 128 (22): 3267.

https://doi.org/10.1182/blood.V128.22.3267.3267

Published: 2016

Journal Articles

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Katja Weisel, MD, Meletios A Dimopoulos, Niels W.C.J. van de Donk, MD PhD, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld

Blood (2016) 128 (22): 3311.

https://doi.org/10.1182/blood.V128.22.3311.3311

Published: 2016

Journal Articles

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Nicola Maciocia, MBChB, BSc, MRCP, Andrew Melville, MBBS, MA (Cantab), MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Simon Cheesman, BPharm, Faye Sharpley, MBBChir, MA, MRCP, MSc, Karthik Ramasamy, MD PhD, Matthew Streetly, BMBS, MRCP, MRCPath, Matthew W Jenner, MD, Reuben Benjamin, MB, BS, FRCPath, Stephen A Schey, MD, Rakesh Popat, Shirley D'Sa, Ali Rismani, MBBS, Kwee L Yong, Neil Rabin

Blood (2016) 128 (22): 3312.

https://doi.org/10.1182/blood.V128.22.3312.3312

Published: 2016

Journal Articles

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Rakesh Popat, MBBS, PhD, Sarah R Brown, Louise M Flanagan, Andrew Hall, Bhuvan Kishore, MBBS, FRPATH, MRCP, Matthew Streetly, Heather E Oakervee, Simon L. Hallam, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Kwee L Yong, MBChB, PhD, Gordon Cook, MD PhD, James D. Cavenagh, MD

Blood (2015) 126 (23): 1826.

https://doi.org/10.1182/blood.V126.23.1826.1826

Published: 2015

Journal Articles

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Karthik Ramasamy, Meletios A. Dimopoulos, Niels W.C.J. van de Donk, Barbara Gamberi, Frank Bridoux, Matthew Streetly, Elisabeth Kueenburg, Barbara Rosettani, Shona Collins, Frederik Lersch, Pamela Bacon, Katja C. Weisel, Pieter Sonneveld, MD PhD

Blood (2015) 126 (23): 374.

https://doi.org/10.1182/blood.V126.23.374.374

Published: 2015

Journal Articles

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Blood (2014) 124 (21): 4745.

https://doi.org/10.1182/blood.V124.21.4745.4745

Published: 2014

Journal Articles

BK Virus (BKV) Associated Haemorrhagic Cystitis Is Associated with Graft Versus Host Disease (GVHD) and Significant Morbidity Post Haematopoietic Stem Cell Transplant (HSCT).

Alesia Abigael Hunt, MBChB MRCP, Anjum Bashir Khan, MBChB, MRCP, Donal McLornan, MD, PhD, Majid A Kazmi, BmedBiol MB ChB MRCP(UK) MRCPath, Matthew Streetly, BMBS, MRCP, MRCPath, Victor Noriega, MD, Eithne MacMahon, Kavita Raj, MD, PhD, MRCP, FRCPath

Blood (2012) 120 (21): 3040.

https://doi.org/10.1182/blood.V120.21.3040.3040

Published: 2012

NARROW

Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial

Safety and Efficacy of Dara-VTD Induction and Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients Presenting with Renal Failure - a Tertiary Centre UK Experience on Behalf of the UK-MRA

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

High Neoantigen Load Confers a Major Benefit from Autologous Stem Cell Transplantation Compared to Consolidation in Newly Diagnosed Multiple Myeloma

Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

BK Virus (BKV) Associated Haemorrhagic Cystitis Is Associated with Graft Versus Host Disease (GVHD) and Significant Morbidity Post Haematopoietic Stem Cell Transplant (HSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only